Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8323913 | 0.98 | GAA (0.55) | GAAKDM4EHSD17B10NPSR1HPGD | |
| SCHEMBL2735405 | 0.89 | GAA (0.57) | GAAKDM4EHSD17B10NPSR1HPGD | |
| Hydrochloric Acid SCHEMBL214655 | 0.88 | GAA (0.56) | GAAKDM4EHSD17B10NPSR1HPGD | |
| SCHEMBL16576769 | 0.88 | KDM4E (0.56) | GAAKDM4EHSD17B10NPSR1HPGD | |
| SCHEMBL31255199 | 0.88 | KDM4E (0.56) | GAAKDM4EHSD17B10NPSR1HPGD | |
| SCHEMBL30876366 | 0.86 | ALDH1A1 (0.53) | KDM4EHSD17B10HPGDALDH1A1MAPT | |
| SCHEMBL19317367 | 0.86 | ALDH1A1 (0.53) | KDM4EHSD17B10HPGDALDH1A1MAPT | |
| SCHEMBL27642525 | 0.84 | SMN1; SMN2 (0.59) | GAAKDM4EHSD17B10NPSR1HPGD | |
| SCHEMBL14816140 | 0.84 | GAA (0.52) | GAAKDM4EHSD17B10NPSR1HPGD | |
| SCHEMBL12056115 | 0.83 | HPGD (0.45) | GAAKDM4EHSD17B10HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426246-B1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RES INST (TW) | 2024-05-01 | — | — | EP | disclosed |
| US-10544113-B2 | Thiazolidinone compounds and use thereof | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2020-01-28 | — | — | US | disclosed |
| CN-108883099-A | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | 石全 | 2018-11-23 | — | — | CN | disclosed |
| WO-2017155910-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2017-09-07 | — | — | US | disclosed |
| EP-0912182-A4 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO INC (US) | 1999-12-29 | — | — | EP | disclosed |
| US-5990107-A | ADMINISTERING TO INHIBIT THE BINDING OF FIBRINOGEN TO BLOOD PLATELETS IN A MAMMAL; OR TO INHIBIT OSTEOCLAST MEDIATED BONE RESORPTION | MERCK & CO., INC. (US) | 1999-11-23 | — | — | US | disclosed |
| EP-0912175-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1999-09-08 | — | — | EP | disclosed |
| EP-0912182-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| EP-0912175-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 1999-05-06 | — | — | EP | disclosed |
| US-5854245-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-12-29 | — | — | US | disclosed |
| WO-1998000134-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000144-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| EP-0597540-B1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0597540-A1 | Aryl-fused and hetaryl-fused-2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1994-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544113-B2 | Thiazolidinone compounds and use thereof | OPRL1, OPRD1, OPRK1 | GAA 1589/4885KDM4E 3848/4885HSD17B10 285/4885 |
| US-20170253569-A1 | THIAZOLIDINONE COMPOUNDS AND USE THEREOF | OPRL1, OPRD1, OPRK1 | GAA 1589/4885KDM4E 3848/4885HSD17B10 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.